ABBV-621

DRUG2 trials

Sponsors

AbbVie, AbbVie B.V.

Conditions

Advanced Solid TumorsCancerCancer Solid tumors and hematologic malignanciesHematologic Malignancies

Phase 1

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

CompletedNCT03082209

AbbVieAdvanced Solid Tumors, Cancer, Hematologic Malignancies

Start: 2017-03-20End: 2022-01-21Updated: 2022-12-09

Unknown Phase

An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies

Active, not recruitingNL-OMON49604

AbbVie B.V.Cancer Solid tumors and hematologic malignancies

Start: 2017-08-22Target: 35Updated: 2024-02-28

Related Papers

Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.

2023-11-302 citations

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Blood2023-01-3129 citations

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

Investigational New Drugs2022-04-2527 citations

Abstract 940: The combinatorial activity of Eftozanermin ABBV621, a novel and potent TRAIL receptor agonist fusion protein, in pre-clinical models of hematologic malignancies

Cancer Research2021-07-01

Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors

Cancer Research2021-03-0949 citations

The Combinatorial Activity of Eftozanermin (ABBV-621), a Novel and Potent TRAIL Receptor Agonist Fusion Protein, in Pre-Clinical Models of Hematologic Malignancies

Blood2020-11-043 citations

A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Blood2020-11-043 citations

Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.

Journal of Clinical Oncology2020-05-20

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood2019-11-1311 citations

Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.

Journal of Clinical Oncology2019-05-2019 citations